Topics:

Niacin Revived as Option for Treating Hyperlipidemia

Niacin Revived as Option for Treating Hyperlipidemia

Niacin may still be a viable therapy in preventive cardiology, despite the findings of no benefits and a signal of harm in the recently stopped Heart Protection Study2—Treatment of HDL to Reduce Incidence of Vascular Events (HPS2-THRIVE) trial, according to these commentators. They note that including the prostaglandin-inhibitor laropiprant in the trial may have negated some of niacin’s benefits. Niacin therapy may be on life support, they admit, but perhaps it should be be resuscitated.

RESULT: Niacin Therapy Lives for Another Day—Maybe?
Journal of the American College of Cardiology | May 28, 2013 (FREE FULL TEXT)

In addition to the effects of niacin in raising high-density lipoprotein (HDL) cholesterol and lowering low-density lipoprotein (LDL) cholesterol and triglycerides, this recent large, systematic review and meta-analysis reported reductions in major cardiovascular disease by 34% and coronary heart disease events by 25% with niacin therapy.  The authors state that the consensus perspective derived from available clinical data supports an effect of niacin in reducing cardiovascular disease events.

RESULT: The Current State of Niacin in Cardiovascular Disease Prevention
Journal of the American College of Cardiology | Jan 20, 2013 (FREE FULL TEXT)

 

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.